{"id":409516,"date":"2021-01-06T09:03:15","date_gmt":"2021-01-06T14:03:15","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409516"},"modified":"2021-01-06T09:03:15","modified_gmt":"2021-01-06T14:03:15","slug":"novavax-to-participate-in-upcoming-conferences-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/","title":{"rendered":"Novavax to Participate in Upcoming Conferences"},"content":{"rendered":"
\n

GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\n J.P. Morgan 39<\/strong>
\n
\n th<\/strong>
\n <\/sup>
\n Annual Healthcare Conference <\/strong>
\n \n <\/td>\n<\/tr>\n
\n Presentation<\/em>
\n \n <\/td>\n<\/tr>\n
Date:<\/td>\nMonday, January 11, 2021<\/td>\n<\/tr>\n
Time:<\/td>\n8:20 a.m. Eastern Time (ET)<\/td>\n<\/tr>\n
Presenters:<\/td>\nStanley C. Erck, President and Chief Executive Officer and
Gregory M. Glenn, M.D., President, Research and Development<\/td>\n<\/tr>\n
Webcast:<\/td>\n\n www.novavax.com<\/a>, \u201cInvestors\u201d \/ \u201cEvents\u201d<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Conference<\/em>
\n \n <\/td>\n<\/tr>\n
Event:<\/td>\nInvestor meetings<\/td>\n<\/tr>\n
Date:<\/td>\nMonday, January 11, 2021 \u2013 Wednesday, January 13, 2021<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n\n\n\n\n
\n 13<\/strong>
\n
\n th<\/strong>
\n <\/sup>
\n Annual Biotech Showcase<\/strong>
\n \n <\/td>\n<\/tr>\n
\n Panel<\/em>
\n \n <\/td>\n<\/tr>\n
Date:<\/td>\nFriday, January 8, 2021<\/td>\n<\/tr>\n
Time:<\/td>\n11:00 a.m. Eastern Time (ET)<\/td>\n<\/tr>\n
Panel title:<\/td>\nIn Conversation with COVID-19 Leaders: The Novavax COVID-19 Journey<\/td>\n<\/tr>\n
Moderator:<\/td>\nKimberly Ha, Founder and Chief Executive Officer, KKH Advisors<\/td>\n<\/tr>\n
Panelist:<\/td>\nJohn J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, Novavax<\/td>\n<\/tr>\n
Webcast:<\/td>\nA replay of the recorded fireside session will be available through the events page of the Company\u2019s website at ir.novavax.com for 90 days.<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About NVX-CoV2373
<\/strong>NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax\u2019 recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein. It is adjuvanted with Novavax\u2019 patented saponin-based Matrix-M\u2122 to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in Phase 1\/2 clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that completed enrollment in November and a trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: a Phase 2b trial in South Africa, and a Phase 1\/2 continuation in the U.S. and Australia.<\/p>\n

\n About Matrix-M\u2122<\/strong>
\n
Novavax\u2019 patented saponin-based Matrix-M\u2122 adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.<\/p>\n

\n About Novavax<\/strong>
\n
Novavax, Inc.\u202f(Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company\u2019s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax\u202fis conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu\u2122, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax\u2019 proprietary saponin-based Matrix-M\u2122 adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.<\/p>\n

For more information, visit www.novavax.com<\/a> and connect with us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Novavax Forward Looking Statements<\/strong>\n <\/p>\n

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading \u201cRisk Factors\u201d in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.<\/p>\n

Contacts: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Investors<\/u>
Erika Trahan
ir@novavax.com<\/a>
240-268-2022<\/p>\n

\n Media<\/u>
\n
Brandzone\/KOGS Communication
Edna Kaplan
media@novavax.com<\/a>
617-974-8659<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation. J.P. Morgan 39 th Annual Healthcare Conference Presentation Date: Monday, January 11, 2021 Time: 8:20 a.m. Eastern Time (ET) Presenters: Stanley C. Erck, President and Chief Executive Officer andGregory M. Glenn, M.D., President, Research and Development Webcast: www.novavax.com, \u201cInvestors\u201d \/ \u201cEvents\u201d \u00a0 \u00a0 Conference Event: Investor meetings Date: Monday, January 11, 2021 \u2013 Wednesday, January 13, 2021 13 th Annual Biotech Showcase Panel Date: Friday, January 8, 2021 Time: 11:00 a.m. Eastern … <\/p>\n

Continue reading “Novavax to Participate in Upcoming Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409516","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNovavax to Participate in Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax to Participate in Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation. J.P. Morgan 39 th Annual Healthcare Conference Presentation Date: Monday, January 11, 2021 Time: 8:20 a.m. Eastern Time (ET) Presenters: Stanley C. Erck, President and Chief Executive Officer andGregory M. Glenn, M.D., President, Research and Development Webcast: www.novavax.com, \u201cInvestors\u201d \/ \u201cEvents\u201d \u00a0 \u00a0 Conference Event: Investor meetings Date: Monday, January 11, 2021 \u2013 Wednesday, January 13, 2021 13 th Annual Biotech Showcase Panel Date: Friday, January 8, 2021 Time: 11:00 a.m. Eastern … Continue reading "Novavax to Participate in Upcoming Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T14:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novavax to Participate in Upcoming Conferences\",\"datePublished\":\"2021-01-06T14:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/\"},\"wordCount\":749,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/\",\"name\":\"Novavax to Participate in Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=\",\"datePublished\":\"2021-01-06T14:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novavax-to-participate-in-upcoming-conferences-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax to Participate in Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/","og_locale":"en_US","og_type":"article","og_title":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","og_description":"GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax\u2019 COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation. J.P. Morgan 39 th Annual Healthcare Conference Presentation Date: Monday, January 11, 2021 Time: 8:20 a.m. Eastern Time (ET) Presenters: Stanley C. Erck, President and Chief Executive Officer andGregory M. Glenn, M.D., President, Research and Development Webcast: www.novavax.com, \u201cInvestors\u201d \/ \u201cEvents\u201d \u00a0 \u00a0 Conference Event: Investor meetings Date: Monday, January 11, 2021 \u2013 Wednesday, January 13, 2021 13 th Annual Biotech Showcase Panel Date: Friday, January 8, 2021 Time: 11:00 a.m. Eastern … Continue reading \"Novavax to Participate in Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T14:03:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novavax to Participate in Upcoming Conferences","datePublished":"2021-01-06T14:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/"},"wordCount":749,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/","name":"Novavax to Participate in Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=","datePublished":"2021-01-06T14:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTUwMiMzOTA3MDU3IzIwMTkwMzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novavax-to-participate-in-upcoming-conferences-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novavax to Participate in Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409516"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409516\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}